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Abstract 
Background: At a World Health Organization (WHO) sponsored meeting it was concluded that there is an urgent 
need for a reference preparation that contains antibodies against malaria antigens in order to support serology 
studies and vaccine development. It was proposed that this reference would take the form of a lyophilized serum or 
plasma pool from a malaria-endemic area. In response, an immunoassay standard, comprising defibrinated human 
plasma has been prepared and evaluated in a collaborative study.
Results: A pool of human plasma from a malaria endemic region was collected from 140 single plasma donations 
selected for reactivity to Plasmodium falciparum apical membrane antigen-1 (AMA-1) and merozoite surface pro-
teins (MSP-119, MSP-142, MSP-2 and MSP-3). This pool was defibrinated, filled and freeze dried into a single batch of 
ampoules to yield a stable source of naturally occurring antibodies to P. falciparum. The preparation was evaluated 
by an enzyme-linked immunosorbent assay (ELISA) in a collaborative study with sixteen participants from twelve 
different countries. This anti-malaria human serum preparation (NIBSC Code: 10/198) was adopted by the WHO Expert 
Committee on Biological Standardization (ECBS) in October 2014, as the first WHO reference reagent for anti-malaria 
(Plasmodium falciparum) human serum with an assigned arbitrary unitage of 100 units (U) per ampoule.
Conclusion: Analysis of the reference reagent in a collaborative study has demonstrated the benefit of this prepara-
tion for the reduction in inter- and intra-laboratory variability in ELISA. Whilst locally sourced pools are regularly use 
for harmonization both within and between a few laboratories, the presence of a WHO-endorsed reference reagent 
should enable optimal harmonization of malaria serological assays either by direct use of the reference reagent or 
calibration of local standards against this WHO reference. The intended uses of this reference reagent, a multivalent 
preparation, are (1) to allow cross-comparisons of results of vaccine trials performed in different centres/with different 
products; (2) to facilitate standardization and harmonization of immunological assays used in epidemiology research; 
and (3) to allow optimization and validation of immunological assays used in malaria vaccine development.
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Background
Malaria is a major public health problem with 91 coun-
tries, inhabited by a total of 3.4 billion people, with 
on-going malaria transmission. In 2015, there were 
approximately 212 million cases of malaria resulting in 
about 429,000 deaths, most of which were children under 
5 years old [1].
A working group on laboratory methods for malaria 
vaccines under the auspices of the World Health Organi-
zation (WHO), Initiative for Vaccine Research (IVR), 
PATH Malaria Vaccine Initiative (MVI) and The National 
Institute of Allergy and Infectious Diseases (NIAID) 
agreed in a meeting held in September 2005, that an 
immunoassay standard for Plasmodium falciparum 
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malaria antibodies was urgently needed to support vac-
cine development particularly in immunological assays 
development and standardization; also for harmonization 
of immunological assays used in epidemiology research 
of malaria [2]. It was proposed that this reference mate-
rial would take the form of a lyophilized serum or plasma 
pool from a malaria-endemic area. The anti-malaria (P. 
falciparum) human serum reference reagent was con-
sidered as important in the progress of malaria vaccine 
development, especially in immunological assays devel-
opment and standardization. WHO ECBS endorsed this 
proposal in 2005.
The reference reagent contains anti-malarial antibod-
ies for multiple antigens and malaria species, but the ini-
tial standardization exercise concentrated on antibodies 
to P. falciparum apical membrane antigen-1 (AMA-1) 
and merozoite surface proteins (MSPs). This manuscript 
describes the collection, production and evaluation of 
this plasma pool leading to the establishment of the first 
International Reference Reagent for anti-malaria (Plas-
modium falciparum) human serum as well as a further 
study describing the presence of anti-CSP antibodies 
and the range of anti-MSP-119 antibodies from different 
malaria species.
Methods
Protein antigens
Escherichia coli-derived: EcMSP3 (FVO), EcMSP-142 
(3D7), EcMSP-142 (FUP), EcMSP-142 (FVO) and Pichia 
pastoris-derived: Pp AMA1 (3D7), PpAMA1 (FVO), 
PpAMA1 (L32) PpCSP-M3 (3D7) proteins were obtained 
from the Malaria Vaccine Development Branch, NIAID/
NIH, Rockville, MD 20852, USA.
Recombinant MSP-119 from P. falciparum, Plasmodium 
vivax, Plasmodium malariae and Plasmodium ovale was 
obtained from The European Malaria Reagent Repository 
(http://www.malariaresearch.eu).
Donation of plasma samples
A proposal to collect malaria reactive plasma samples 
was developed and approved by the ethical boards of 
CDC and KEMRI and the Kenyan National Blood Bank 
Transfusion Services (KNBTS), and agreed by the Chief 
Medical Officier (CMO), Kenya Ministry of Health. As 
a result, in 2009, 140 plasma samples (20–50 ml volume 
and malaria reactive) were collected, screened for HIV, 
HBV and HCV by the blood bank, CDC, Kisumu, and 
sent to NIBSC, U.K. by the KEMRI/CDC.
Lyophilization of anti‑malaria defibrinated plasma pool 
(10/198)
At NIBSC, the plasma samples were initially screened 
by ELISA against five P. falciparum antigens; AMA-1, 
MSP-119, MSP-142, MSP-2 and MSP-3. Samples with 
high titre anti-AMA-1 were pooled into four groups and 
defibrinated. The resulting serum was pooled, diluted 
1:5 with sterile distilled water without any other excipi-
ents and filtered (1.2, 0.45 then 0.22 µm). No other buffer, 
bulking agent or stabilizer was used. The definitive fill 
was performed within the Standards Processing Divi-
sion of NIBSC using a Bausch & Strobel Filling Machine 
(AFV5090). The diluted serum preparation was stirred 
constantly during filling to ensure homogeneity of fill 
and the temperature was maintained between 4 and 8 °C. 
DIN clear glass ampoules with capacity of 5  ml volume 
were used. Freeze-drying was performed using a 4-day 
cycle and the finished product was coded 10/198 and 
stored in the dark at −20 °C except for a small number of 
ampoules used for an accelerated degradation study.
A single batch of about 5000 ampoules was pro-
duced. The ampoules have an average actual fill weight 
of 1.0085  g per ampoule; with a target CV of precision 
of filling for fill mass of <0.25%, where the actual CV of 
fill mass was 0.11% (of 195 randomly selected ampoule, 
weights being measured). Nitrogen was used to back fill 
the freeze drier chamber at the end of the cycle and hence 
provide the headspace gas for the ampoules. The purity 
of the boiled off nitrogen was certified at 99.99%. Micro-
biological assessment was made on the product pre- and 
post-processing and the bacterial, mould, and yeast col-
ony counts were negligible at pre- and post-filling stages. 
The residual moisture content of this preparation is 0.84% 
as determined by the Abderhalden method, with a CV of 
12%. The mean oxygen head space was determined to be 
0.34% with a CV of 20%. This was determined by taking a 
mean of 12 determinations using frequency modulation 
spectroscopy (FMS), a non-destructive infra-red laser 
absorption technique.
Reference controls
Three additional human serum preparations (as internal 
controls, C1, C2 or C3) representing different titres for 
anti-AMA-1 and anti-MSP-2 were also filled and lyophi-
lized to be included as test samples in the collaborative 
study.
Collaborative study design
Participants
The candidate WHO Reference Reagent (Code: 10/198) 
was distributed to sixteen participating laboratories 
in twelve different countries (The Collaborative Study 
Group, see Acknowledgements). All invited participants 
were sent a questionnaire asking them to confirm having 
extensive experience in ELISA. The collaborative study 
involved a wide range of appropriately qualified labora-
tories representing clinical and research laboratories, 
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academia, not-for-profit research organizations, govern-
ment-funded organizations and charitable organizations 
worldwide covering Africa, Asia, Europe and the USA. 
For this study, a code number was allocated at random to 
each participant.
ELISA protocol for collaborative study
Each participant was provided with 4 ampoules of posi-
tive control (XC) and 4 sets of nine blinded test sam-
ples (labelled with just the sample number) comprising 
coded duplicates of the 10/198 (coded S1 and S2 in this 
study) and internal controls. C1, C2 or C3 (see Table 1). 
The internal controls are also malaria reactive plasma 
pools from Kenya that were selected to provide a range 
of responses by ELISA thus ensuring a breadth of relative 
potencies for analysis in the collaborative study. Partici-
pants were requested to test nine blinded samples and a 
positive control as labelled using a specific study proto-
col. All ELISA plates included duplicates of 10/198 which 
were coded as ‘S1’ (sample numbers 1, 4 and 8) or ‘S2’ 
(sample numbers 2, 6 and 9) for statistical analysis.
In brief, 96-well ELISA plates (Immulon 4, flatbot-
tom) were coated with 50 µl of antigen (2 µg/ml) in coat-
ing buffer (1.59  g  Na2CO3  +  2.93  g  NaHCO3 per litre 
in deionized water, pH 9.4–9.6). The coated plates were 
sealed and stored overnight at 4 °C. After 3 washes with 
PBS-0.05% Tween 20 (PBS-T) plates were blocked with 
200  µl of 1% skimmed milk (w/v) in PBS-T (diluent 
buffer) for 3 h at room temperature. Plates were washed 
a further 3 times in PBS-T, followed by adding 100 µl of 
diluent buffer into all wells.
Test samples and controls were reconstituted in 1  ml 
deionized water and mixed. To Column 1, 50 µl of recon-
stituted test samples or XC was added in duplicate to 
each well. A threefold serial dilution was prepared in dil-
uent buffer across the entire plate. Plates were sealed and 
incubated overnight at 4 °C.
Plates were washed 6 times in PBS-T and 100 µl HRP-
conjugated rabbit anti-human IgG (DAKO, 1:5000 in 
diluent buffer) was added before incubation for 3  h at 
room temperature. Plates were washed a further 6 times 
before colour development by addition of 100 µl/well of 
OPD substrate solution prepared as per the manufactur-
ers instruction. The reaction was stopped by addition 
of 25 µl/well 2 M  H2SO4 and absorbance at 492 nm was 
measured using a plate reader.
Participants were asked to perform three independent 
experiments on each set of samples, for three different 
coating antigens, using freshly reconstituted ampoules on 
each experimental day. For each experimental day a total 
of 27 antigen-coated plates were required for the three 
different antigens (MSP3, MSP-142 and AMA-1 3D7; i.e. 
9 plates per antigen). The plate layout was such that each 
ELISA plate would generate results for two individual 
samples of 10/198 (S1 and S2), the positive control (XC) 
and an internal control (C1, C2 or C3).
All raw data from participants were sent and collated at 
NIBSC for statistical analysis.
Stability studies
The stability studies were performed at NIBSC only. Two 
independent ELISA experiments (as above) were per-
formed for each antigen; three individual ampoules of 
each sample group were tested for each experiment.
Accelerated thermal degradation: ampoules of the 
10/198 were stored at −150, −70, −20, 4, 20, 37, 45, or 
56  °C, for 1, 3, 6, 9, 12, 18, or 24 months. At each time 
point the ampoules stored at the various temperatures 
were transferred to storage at −20 °C until further anal-
ysis. The stability samples (stored at various tempera-
tures and at the fixed time points) were reconstituted 
and assessed using the same ELISA method described as 
above and compared to 10/198 stored at −150 °C.
In use stability after reconstitution: Ampoules were 
reconstituted in deionized water and stored at 4 or 
−20 °C for 1 or 3 months. After storage the samples were 
analysed and compared to freshly opened and reconsti-
tuted samples in the ELISA assay.
Statistical analysis
The potencies of all samples were calculated relative to 
10/198 (S1) for each antigen from each participant labo-
ratory by analysis of the raw optical density assay data. 
Log transformed absorbance values were used as the 
assay response in all cases. As a large volume of data of 
varying quality was received, full curves were not fitted 
and analysis was based only on an approximately lin-
ear section of the response range by excluding serum 
dilutions with responses falling outside 20–80% of the 
response range observed on the plate. Where this gave 
Table 1 Samples provided to  the collaborative study par-
ticipants
Sample number Product code Product name
Control Pool 4 Positive control (XC)
1 10/198 Reference Reagent (S1)
2 10/198 Reference Reagent (S2)
3 Pool 2 Control 2 (C2)
4 10/198 Reference Reagent (S1)
5 12/192 Control 3 (C3)
6 10/198 Reference Reagent (S2)
7 Pool 1 Control 1 (C1)
8 10/198 Reference Reagent (S1)
9 10/198 Reference Reagent (S2)
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fewer than three dilutions for analysis the sample was 
excluded. As this resulted in an excessive number of 
exclusions in laboratories 3, 10 and 15, the response 
range was extended to 10–90% for these laboratories.
The assays were analysed with a weighted logistic par-
allel line model, using custom software, WRANL [3]. 
Assays where visual assessment of the plotted data clearly 
indicated that a parallel line model would not fit the data 
were excluded from further analysis. Assay validity was 
assessed by calculation of the ratio of slopes for each test 
sample relative to S1. The samples were concluded to 
be non-parallel when the slope ratio was outside of the 
range 0.67–1.50 and no estimates were reported. Where 
potency estimates were calculated,  EC50 estimates (con-
centration required to achieve a 50% response) were also 
determined in order to assess their variability within and 
between laboratories.
Relative potency and  EC50 estimates from all valid 
assays were combined to generate an unweighted geo-
metric mean (GM) for each laboratory and these labora-
tory means were used to calculate an overall unweighted 
geometric mean for each sample. Variability between 
assays within laboratories and between laboratories has 
been expressed using geometric coefficients of varia-
tion (GCV = {10s − 1} × 100% where s is the standard 
deviation of the  log10 transformed estimates). Analysis 
of variance with Duncan’s multiple range test [4] using 
the log transformed potency estimates was used to com-
pare laboratories and samples (p < 0.05 used to conclude 
significance).
Cross reactivity with other antigens
The cross reactivity of 10/198 with circumsporozoite pro-
tein (CSP) or MSP-119 from different malaria species (P. 
falciparum, P. vivax, P. ovale or P. malariae) was investi-
gated by ELISA (as above with few modifications). These 
experiments were performed at NIBSC only.
CSP ELISA; ELISA plates were coated at 2  µg/ml 
PpCSP in coating buffer overnight at 4 °C. Caesin (1% w/v 
in PBS-T) was used as the blocking agent. TMB (100 µl) 
was used as peroxidase substrate for colour reaction 
which was stopped after 20 min by addition of 50 µl 1 M 
 H2SO4. Plates were read on a Multiskan EX plate reader 
(Thermofisher) in absorbance mode at 450 and 620 nm. 
The absorbance background values at 620 nm were sub-
tracted from those at 450 nm. In addition OD from nega-
tive control wells (no antigen) were subtracted from the 
OD of experimental samples.
In addition the intended use of 10/198 was demon-
strated for potency evaluation of several test samples. 
These additional test samples (sample 23, 25 or 34) were 
from malaria reactive plasma packs stored at NIBSC. 
The data were analysed using CombiStats ver 5.0 (http://
combistats.edqm.eu/) with a sigmoid curves model 
to determine potencies of the test samples relative to 
10/198.
Competitive MSP-119 ELISA was conducted similar to 
previous reports for mixed AMA-1 alleles [5] and was 
divided into two stages using 2 µg/ml of species specific 
recombinant MSP-119 (Pf, Pm, Pv, Po) as coating anti-
gens. In Stage one, a tritration of 10/198 was conducted 
to establish an optimal dilution factor that achieves a 
response in the approximately linear region of the dose 
response range (ca. 20–80%). This optimal dilution factor 
of 10/198 was then used in Stage two ELISA in the pres-
ence of the four recombinant MSP-119s (at various con-
centrations). In brief, the plate was coated and blocked as 
before (2 µg/ml antigen) and then varying concentrations 
of competitor MSP-119 (50 µl) was added in twofold dilu-
tion across a 96-well plate to deliver a highest concen-
tration of 30 µg/ml MSP-119 (from each of the species). 
This was followed by the 10/198 at the optimal dilution 
determined in stage one. The remainder procedure of the 
ELISA was performed as previously described.
Results and discussion
Data returned from study participants
The analysis of 10/198 was conducted by 16 different 
laboratories, data from a total of 1227 ELISA plates were 
received for statistical analysis (409 per antigen type). 
Data from experiment 1 for Laboratory 3 were not ana-
lysed as the substrate used was not consistent with that 
used in experiments 2 and 3. No other such inconsisten-
cies were reported. Analysis of the remaining assays as 
described above gave valid estimates of relative potency 
in 93.6, 92.1 and 92.7% of cases for AMA-1, MSP-142 and 
MSP-3, respectively.
Relative potencies of S1 and S2
Relative potency estimates for the two individual 
ampoules of 10/198 (S1 and S2) are summarized in Addi-
tional file  1: Table S1. The agreement between potency 
estimates for S1 and S2 within plates can be assessed 
using the intra-laboratory geometric coefficients of vari-
ation (GCVs). These represent the variability between 
assays of direct comparisons of the duplicate samples. 
They range from 4.9% (Laboratory 16, MSP-142 anti-
gen), showing good agreement, to 73.2% (Laboratory 10, 
AMA-1 antigen), showing a high level of variability. In 
the majority of cases, GCVs were generally less than 30%.
Analysis of potency relative to 10/198 reduces inter 
laboratory variation
Analysis of the log potencies by Duncan’s multiple range 
test was used to determine any ‘outlier’ laboratories by 
indicating cases where a laboratory’s estimates differed 
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significantly from those obtained in all other laboratories. 
This was the case for Laboratory 2 (sample XC, all anti-
gens), Laboratory 3 (sample C1, MSP-3 antigen), Labora-
tory 4 (sample XC, all antigens; sample C3, AMA-1 and 
MSP-142 antigens) and Laboratory 13 (sample XC, MSP-3 
antigen; sample C1, AMA-1 antigen; sample C2, AMA-1 
and MSP-142 antigens). All overall means and GCVs are 
therefore shown both including and excluding Laborato-
ries 2, 3, 4 and 13 (Additional file 1: Tables S2–S7).
Table  2 summarizes the inter-laboratory variations 
after exclusion of outliers and demonstrates the benefits 
of determining relative potency rather than using  EC50 as 
an absolute measure of potency. The observed GCVs are 
higher if  EC50 data were considered with a range of 46.6–
82.7%. However, when relative potency (to reference 
reagent 10/198) is calculated the GCVs reduced consid-
erably to 5.4–13.9%. Without the exclusion of outliers the 
same trend remains (GCV range 46.6–82.7% for  EC50, 
9.5–55.6% for relative potency, Additional file  1: Tables 
S1–S7). Similarly to the inter laboratory data there is a 
reduction in the intra-laboratory variability when relative 
potency is used in place of  EC50, albeit a smaller one.
Figure 1 shows box-histograms of the observed relative 
potency (when 10/198 is used as a reference reagent) and 
1/EC50 for the four test samples (C1, C2, C3 and XC). In 
each case a reduction in the inter laboratory variations 
can be seen when relative potency is reported instead 
of 1/EC50. These data demonstrate the benefit of using 
10/198 as a common reference reagent across assays and 
laboratories.
Reference reagent 10/198 is stable at elevated 
temperature and after reconstitution
The reference reagent 10/198 has been lyophilized to 
maximize the long-term stability for storage and ship-
ment. The thermal stability was assessed in a degrada-
tion study at elevated temperatures over a range of time 
points. The 24  month samples were analysed at NIBSC 
using the same ELISA protocol as in the collaborative 
study. The samples were readily reconstituted within 
1  min, except for the ampoules stored at 56  °C, which 
required approximately 1–2 min instead to be fully recon-
stituted. Geometric mean potency estimates of samples 
stored at different temperatures for 24 months (expressed 
relative to those stored at −150 °C) are shown in Fig. 2a. 
Statistical analysis indicated that there was no detectable 
loss of reactivity even at 45 °C for 24 months, for AMA-1, 
MSP-142 or MSP-3. At 56 °C for both MSP-142 and MSP-3 
no loss of activity was seen. Based on these data there was 
insufficient degradation to predict a yearly loss for 10/198.
In use stability after reconstitution in deionized water 
was assessed at −20 or 4 °C for 1 or 3 months. By com-
parison to freshly reconstituted preparation there is no 
evidence of any significant loss in relative potency of 
reconstituted content after storage for 3 months (Fig. 2b).
The use of Reference Reagent 10/198 as a standard for 
the calibration of serology assays has resulted in a signifi-
cant decrease in inter and intra-laboratory variations and 
thus demonstrates the benefit of using this reagent for 
standardization of P. falciparum serological experiments. 
Furthermore the lyophilized preparation shows no loss in 
reactivity under accelerated degradation conditions and 
is stable for up to 3  months after reconstitution at 4  °C 
or lower. The preparation is maintained under controlled 
storage conditions at NIBSC on behalf of WHO and is 
ready for worldwide distribution when requested.
Unitage proposal
There is currently no WHO International Standard/Ref-
erence Reagent of human antiserum for any species of 
malaria. As there is no suitable preparation with known 
unitage for the calibration of 10/198, it was proposed to 
WHO ECBS, and agreed by participants, that this the 
first WHO Reference Reagent for Anti-Malaria (P. falci-
parum) human serum contains an arbitrary unitage of 
100 Units per ampoule.
Reference reagent 10/198 recognizes CSP of Plasmodium 
falciparum
The collaborative study was designed to test the suitabil-
ity of 10/198 to act as a reference reagent for serology 
studies against P. falciparum antigens. The study assessed 
the binding of the reference serum to the merozoite anti-
gens AMA-1, MSP-142 and MSP3. However, the most 
advanced malaria vaccine candidate RTS,S is targeted 
against the pre-erythrocytic antigen, CSP. In July 2015 
the vaccine candidate RTS,S/AS01 received a positive 
scientific opinion from the European Medicines Agency 
for the prevention of malaria in children aged 6 weeks to 
17 months in sub-Saharan Africa [5].
Table 2 Potency (relative to  S1) and   EC50 estimates 
for samples XC, C1, C2 and C3
Antigen Sample
XC C1 C2 C3
A. Potency relative to S1: Between-laboratory geometric mean and geomet-
ric coefficient of variation (%) after exclusion of laboratories 2, 3, 4 and 13
AMA-1 0.809 (9.6%) 3.549 (8.2%) 0.870 (5.7%) 0.014 (12.5%)
MSP-142 0.493 (8.3%) 2.447 (8.4%) 0.871 (6.6%) 0.033 (11.5%)
MSP-3 0.548 (7.9%) 3.026 (6.2%) 0.812 (5.4%) 0.041 (13.9%)
B. EC50 estimates: Between-laboratory geometric mean and geometric coef-
ficient of variation (%) after exclusion of laboratories 2, 3, 4 and 13
AMA-1 0.071 (79.7%) 0.016 (62.4%) 0.069 (69.5%) 3.849 (82.7%)
MSP-142 0.309 (52.8%) 0.061 (48.1%) 0.167 (56.0%) 4.406 (46.6%)
MSP-3 0.620 (60.6%) 0.108 (63.9%) 0.441 (53.6%) 7.892 (62.0%)
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Therefore, a separate investigation at NIBSC sought 
to determine if 10/198 could act as a reference reagent 
for detecting other malarial antigens. The reactivity of 
10/198 to a recombinant CSP produced in Pichia was 
evaluated. Figure 3 shows that 10/198 is able to recognize 
CSP in a similar ELISA protocol as used in the collabora-
tive study and, as a demonstration, this reference reagent 
was used to assign units to three plasma samples based 
Fig. 1 Inter-laboratory variability is reduced when potency relative to the reference reagent 10/198 replaces direct measurement. Box histograms 
show ELISA derived values for 1/EC50 (left) and potency (right) for samples C1, C2, C3 and XC from each laboratory (1–16) with AMA-1 as the coating 
antigen (a), MSP-142 as the coating antigen (b), and MSP-3 (c)
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on the designation of 10/198. Figure 3 shows sample 23 
had a relative potency of 22.7 U/ml (95% CL 13.8–37.5), 
considerably less potent than 10/198 while samples 25 
and 34 had values of 462.8 (95% CL 404.9–529.0) and 
1653.1 (95% CL 1283.8–2128.5)  U/ml. These data dem-
onstrate that 10/198 also contains antibodies recogniz-
ing CSP and could be of beneficial as a reference reagent 
beyond the scope of the antigens tested in the collabora-
tive study.
Reference plasma 10/198 binds to  PmMSP119 
and  PoMSP119 but not  PvMSP119
It was also expected that 10/198, which was prepared 
from a pool of plasma samples from a malaria-endemic 
area, may contain antibodies from malaria species other 
than P. falciparum. To investigate this, ELISA was per-
formed using recombinant MSP-119 from each of P. falci-
parum, P. vivax, P. malariae and P. ovale. The relative titre 
of antibodies to each of these antigens is shown in Fig. 4. 
These data indicate 10/198 has significant reactivity with 
P. malariae MSP-119 and P. ovale MSP-119 but no signifi-
cant reactivity with P. vivax MSP-119 as could be expected 
with plasma samples collected in East Africa. Competi-
tive ELISA (Fig.  4b) was used to investigate the species 
specificity of the binding to each individual MSP-119. 
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Fig. 2 Reference reagent 10/198 is stable at elevated temperature for 
24 months and after reconstitution. a Relative potency measured by 
ELISA, compared to storage at −150 °C, after 24 months storage.  
b Relative potency measured by ELISA, compared to freshly reconsti-
tuted 10/198, after storage of reconstituted content for 3 months
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Fig. 3 Reference reagent 10/198 detects recombinant PpCSP in ELISA. Serum dilution (Log) vs absorbance (AU) was measured for 10/198 and three 
unknown samples by ELISA with PpCSP as the coating antigen. Each ampoule of 10/198 contains 100 Units as assigned unitage. Parallel line analysis 
of the data presented in a was used to derive the unitage assigned in test samples (b)
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Only PfMSP-119 (at 30  µg/ml) was able to compete for 
binding when using PfMSP-119 as the coating antigen; 
with similar specificity for PmMSP-119 as evidenced by 
the residual signal reducing to nearly zero when only the 
homologous competitor was used. Some mixed competi-
tion was observed when P. ovale MSP-119 was used as the 
coating antigen with both PmMSP-119 and PoMSP-119 
able to compete at 30 µg/ml. As a control for PvMSP-119 
a lyophilized serum standard (71/281) was used, that was 
derived from a blood transfusion initially diagnosed as P. 
vivax malaria, but not characterized further (Additional 
file 1: Figure S1). These data demonstrate that the refer-
ence reagent 10/198 contains antibodies capable of rec-
ognizing MSP-119 from P. malariae and P. ovale as well as 
P. falciparum. This is not unexpected given the reference 
reagent is derived from a pool of malaria reactive samples 
from adults but with no additional knowledge of prior 
malaria exposure this cannot be unequivocally linked to 
P. malariae or P. ovale infection.
Conclusions
In October 2014, the WHO ECBS adopted this prepa-
ration (10/198) as the first WHO Reference Reagent of 
anti-malaria (Plasmodium falciparum) human serum 
with assigned an arbitrary unitage of 100 units (U) 
per ampoule [6, 7]. It is stored at NIBSC (Code Num-
ber 10/198) for distribution worldwide since 2015. 
This reference reagent should be particularly useful for 
inter-laboratory standardization and harmonization of 
immunological assays used in vaccine development and 
epidemiology. Analysis of reagent requests suggests a 
number of manufacturers and academic research groups 
are making use of the 10/198. It is expected that these 
are predominantly in the field of sero-epidemiology and 
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Fig. 4 Reference reagent 10/198 also contains antibodies that recognize to P. malariae and P. ovale MSP-119 but not P. vivax. a Absorbance (AU) 
resulting from ELISA measuring titration of 10/198 against different coating antigens at 2 µg/ml; MSP-119 from P. falciparum, P. malariae, P. ovale or P. 
vivax. b Residual signal, after competition of 10/198 with 30 µg/ ml of antigen, for each of the different coating antigens
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diagnostics development potentially reflecting a change 
from the expected primary use conceived at the initiation 
of this project.
This reference reagent, whilst evaluated in the collabo-
rative study against a few selected antigens, is expected 
to be constitute a valuable reagent over a far wider range 
of antigens including CSP, the antigen in the malaria vac-
cine, Mosquirix. However, testing has revealed no sig-
nificant levels of antibodies against Rh5, a leading blood 
stage vaccine candidate (Silk and Draper pers. comm). 
The establishment of the first WHO Reference Reagent 
of anti-malaria (P. falciparum) human serum represents a 
pool of serum from Kenyan adults and is intended to act 
as a reference point for serological assays. It is expected 
that local, more geographically relevant, pools may be 
calibrated against this reference reagent as part of a 
broader standardization process.
In addition to use in serology assays this reagent rep-
resents a standard reflecting the antibody composi-
tion consistent with naturally acquired immunity and it 
is expected that it will be beneficial in the standardiza-
tion of a range of functional immunoassays. Osier et al. 
recently demonstrated the activity of pooled human 
IgG from malaria exposed Kenyan adults in an opsonic 
phagocytosis assay [8], although there appears to be little 
growth inhibitory activity for 10/198, when reconstituted 
and applied to standard in vitro culture without further 
manipulation (Bowyer and Khatri unpublished data).
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